Published on in Vol 6, No 2 (2017): February

VESPRO: An Individual Patient Data Prospective Meta-Analysis of Selective Internal Radiation Therapy Versus Sorafenib for Advanced, Locally Advanced, or Recurrent Hepatocellular Carcinoma of the SARAH and SIRveNIB Trials

VESPRO: An Individual Patient Data Prospective Meta-Analysis of Selective Internal Radiation Therapy Versus Sorafenib for Advanced, Locally Advanced, or Recurrent Hepatocellular Carcinoma of the SARAH and SIRveNIB Trials

VESPRO: An Individual Patient Data Prospective Meta-Analysis of Selective Internal Radiation Therapy Versus Sorafenib for Advanced, Locally Advanced, or Recurrent Hepatocellular Carcinoma of the SARAH and SIRveNIB Trials

Journals

  1. Helmberger T, Arnold D, Bilbao J, de Jong N, Maleux G, Nordlund A, Peynircioglu B, Sangro B, Sharma R, Walk A. Clinical Application of Radioembolization in Hepatic Malignancies: Protocol for a Prospective Multicenter Observational Study. JMIR Research Protocols 2020;9(4):e16296 View
  2. Justinger C, Gruden J, Kouladouros K, Stravodimos C, Reimer P, Tannapfel A, Binnenhei M, Bentz M, Tatsch K, Rüdiger T, Schön M. Histopathological changes resulting from selective internal radiotherapy (SIRT). Journal of Surgical Oncology 2018;117(5):1084 View
  3. Mikell J, Dewaraja Y, Owen D. Transarterial Radioembolization for Hepatocellular Carcinoma and Hepatic Metastases: Clinical Aspects and Dosimetry Models. Seminars in Radiation Oncology 2020;30(1):68 View
  4. Palmer D, Hawkins N, Vilgrain V, Pereira H, Chatellier G, Ross P. Tumor burden and liver function in HCC patient selection for selective internal radiation therapy: SARAH post-hoc study. Future Oncology 2020;16(1):4315 View
  5. Walton M, Wade R, Claxton L, Sharif-Hurst S, Harden M, Patel J, Rowe I, Hodgson R, Eastwood A. Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation. Health Technology Assessment 2020;24(48):1 View
  6. Han S, Lee H, Park J, Kim S, Kim D, Ahn S, Han K, Seong J, Won J, Han D, Kim B. <p>Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion</p>. Journal of Hepatocellular Carcinoma 2020;Volume 7:403 View
  7. Rizzo A, Ricci A, Brandi G. Combining immune checkpoint inhibitors with locoregional therapies in hepatocellular carcinoma. Expert Review of Precision Medicine and Drug Development 2022;7(1):1 View
  8. Rizzo A. Locoregional treatments plus immunotherapy in hepatocellular carcinoma: where do we stand?. Future Oncology 2022;18(14):1665 View
  9. Elaimy A, Cao Y, Lawrence T. Evolution of Response-Based Radiotherapy for Hepatocellular Cancer. The Cancer Journal 2023;29(5):266 View